Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Philippe Giguère und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Hematologic Diseases, Receptors, Chimeric Antigen. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor T cells (CAR‐T) have been associated with prolonged hematotoxicity known as late immune effector cell‐associated hematologic toxicity (ICAHT), but there is limited literature on its duration and clinical implications. We conducted a retrospective review of 156 adults who received CD19‐directed CAR‐T therapy at The Ottawa Hospital between 2019 and 2024. Late ICAHT occurred in 39% (95% CI 31%–47%) of recipients, with a duration ranging from 6 to 1473 days. Cumulative incidence analysis, censoring for disease progression and death, yielded a median duration of 183 days, with 20% (95% CI 11%–38%) experiencing ICAHT lasting over 1 year. Overall survival was comparable between patients with and without late ICAHT. In univariate analysis, HEMATOTOX score was significantly associated with the development of late ICAHT. Among a subset of 13 patients assessed for resource utilization, growth factors were the primary cost driver. Patients required frequent follow‐up, with a median of 1 in every 7 days involving an in‐person healthcare encounter. Late ICAHT was a common but usually self‐limited toxicity. The 30‐day cutoff currently used to define late ICAHT should be compared to later cutoffs to evaluate whether it improves the characterization of ICAHT's clinical impact on outcomes and healthcare utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
- Faculty of Medicine, Roger Guindon Hall, University of Ottawa, Ottawa, Ontario, Canada.
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
ORCID-Profile: Philippe Giguère, Connor Prince, Ram Vasudevan Nampoothiri
Zitieren
APA
Giguère, P., Akbarian, N., Prince, C., Thavorn, K., Cieniak, C., Granger, M., Hamelin, L., Nampoothiri, R. V., Kennah, M., & Kekre, N. (2026). Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization. European Journal of Haematology. https://doi.org/10.1111/ejh.70103
Vancouver
Giguère P, Akbarian N, Prince C, Thavorn K, Cieniak C, Granger M, et al. Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization. European Journal of Haematology. 2026. doi:10.1111/ejh.70103
BibTeX
@article{Gigure2026,
author = {Giguère, Philippe and Akbarian, Nicky and Prince, Connor and Thavorn, Kednapa and Cieniak, Carolina and Granger, Matthew and Hamelin, Linda and Nampoothiri, Ram Vasudevan and Kennah, Michael and Kekre, Natasha},
title = {Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70103}
}
EUVIMED